Amgen Reports final analysis Data for Bimekizumab in Lupus nephritis

Amgen today announced final analysis results for Bimekizumab in patients with Lupus nephritis. The study demonstrated that Bimekizumab reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Lupus nephritis and support the continued development of Bimekizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Bimekizumab was consistent with previous observations, with no new safety signals identified.